<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI Disruption Forecast: Eli Lilly ‚Äî Employee Perspective | The 2030 Intelligence Report</title>
    <meta name="description" content="MACRO INTELLIGENCE MEMO">
    <meta property="og:title" content="ENTITY: ELI LILLY &amp; COMPANY - EMPLOYEE PERSPECTIVE">
    <meta property="og:description" content="MACRO INTELLIGENCE MEMO">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ai2030report.com/articles/companies-us-eli-lilly-eli-lilly-employee.html">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="ENTITY: ELI LILLY &amp; COMPANY - EMPLOYEE PERSPECTIVE">
    <meta name="twitter:description" content="MACRO INTELLIGENCE MEMO">
    <link rel="canonical" href="https://ai2030report.com/articles/companies-us-eli-lilly-eli-lilly-employee.html">
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "ENTITY: ELI LILLY & COMPANY - EMPLOYEE PERSPECTIVE",
        "description": "MACRO INTELLIGENCE MEMO",
        "url": "https://ai2030report.com/articles/companies-us-eli-lilly-eli-lilly-employee.html",
        "author": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        },
        "publisher": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        }
    }
    </script>
    <link rel="icon" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect rx='20' width='100' height='100' fill='%233b82f6'/><text x='50' y='70' font-size='55' font-weight='700' text-anchor='middle' fill='white'>30</text></svg>">
    <style>
:root {
    --bg-primary: #0a0a0f;
    --bg-secondary: #111118;
    --bg-card: #16161f;
    --bg-card-hover: #1c1c28;
    --border: #2a2a3a;
    --text-primary: #e4e4ef;
    --text-secondary: #9494a8;
    --text-muted: #6b6b80;
    --accent-blue: #3b82f6;
    --accent-purple: #8b5cf6;
    --accent-amber: #f59e0b;
    --accent-green: #10b981;
    --accent-red: #ef4444;
    --accent-cyan: #06b6d4;
    --gradient-1: linear-gradient(135deg, #3b82f6 0%, #8b5cf6 100%);
}

* {
    margin: 0;
    padding: 0;
    box-sizing: border-box;
}

html {
    scroll-behavior: smooth;
}

body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
    background-color: var(--bg-primary);
    color: var(--text-primary);
    line-height: 1.6;
    letter-spacing: -0.3px;
}

a {
    color: var(--accent-blue);
    text-decoration: none;
    transition: color 0.2s ease;
}

a:hover {
    color: var(--accent-purple);
}

button {
    background: none;
    border: none;
    cursor: pointer;
    font-family: inherit;
}

/* Header */
.site-header {
    position: sticky;
    top: 0;
    z-index: 1000;
    background: rgba(10, 10, 15, 0.95);
    backdrop-filter: blur(10px);
    border-bottom: 1px solid var(--border);
}

.header-inner {
    max-width: 1400px;
    margin: 0 auto;
    padding: 1rem 2rem;
    display: flex;
    align-items: center;
    justify-content: space-between;
}

.site-logo {
    display: flex;
    align-items: center;
    gap: 0.5rem;
    font-weight: 700;
    font-size: 1.5rem;
    color: var(--text-primary);
    text-decoration: none;
}

.logo-mark {
    width: 2rem;
    height: 2rem;
    background: var(--gradient-1);
    border-radius: 0.5rem;
    display: flex;
    align-items: center;
    justify-content: center;
    color: white;
    font-weight: 700;
    font-size: 1.2rem;
}

.logo-text {
    display: flex;
    flex-direction: column;
    gap: 0.125rem;
}

.logo-text-main {
    font-size: 1rem;
}

.logo-text-sub {
    font-size: 0.65rem;
    color: var(--text-secondary);
    letter-spacing: 0.5px;
}

.nav-links {
    display: flex;
    gap: 2rem;
    list-style: none;
}

.nav-links a {
    color: var(--text-secondary);
    font-size: 0.95rem;
    font-weight: 500;
    transition: color 0.2s ease;
}

.nav-links a:hover {
    color: var(--text-primary);
}

.nav-toggle {
    display: none;
    flex-direction: column;
    gap: 0.4rem;
    padding: 0.5rem;
}

.nav-toggle span {
    width: 1.5rem;
    height: 2px;
    background: var(--text-primary);
    transition: all 0.3s ease;
}

/* Hero Section */
.hero {
    max-width: 1400px;
    margin: 0 auto;
    padding: 4rem 2rem;
    text-align: center;
}

.hero h1 {
    font-size: 3rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.hero .tagline {
    font-size: 1.25rem;
    color: var(--text-secondary);
    margin-bottom: 2rem;
}

.hero-stats {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
    gap: 2rem;
    margin-top: 3rem;
    padding-top: 3rem;
    border-top: 1px solid var(--border);
}

.stat {
    text-align: center;
}

.stat-number {
    font-size: 2.5rem;
    font-weight: 700;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.stat-label {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-top: 0.5rem;
}

/* Search and Filter */
.search-container {
    max-width: 1400px;
    margin: 2rem auto;
    padding: 0 2rem;
}

.search-box {
    width: 100%;
    padding: 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 1rem;
    margin-bottom: 1.5rem;
}

.search-box::placeholder {
    color: var(--text-muted);
}

.filter-buttons {
    display: flex;
    gap: 1rem;
    flex-wrap: wrap;
    margin-bottom: 2rem;
}

.filter-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-secondary);
    cursor: pointer;
    font-weight: 500;
    transition: all 0.2s ease;
}

.filter-btn:hover,
.filter-btn.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Article Grid */
.article-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(350px, 1fr));
    gap: 2rem;
}

.article-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
    display: flex;
    flex-direction: column;
    cursor: pointer;
}

.article-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.card-meta {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 1rem;
    flex-wrap: wrap;
    gap: 0.5rem;
}

.card-badge {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(59, 130, 246, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    text-transform: uppercase;
    letter-spacing: 0.5px;
}

.badge-countries {
    background: rgba(59, 130, 246, 0.15);
    color: #3b82f6;
}

.badge-companies {
    background: rgba(139, 92, 246, 0.15);
    color: #8b5cf6;
}

.badge-sectors {
    background: rgba(245, 158, 11, 0.15);
    color: #f59e0b;
}

.badge-actions {
    background: rgba(16, 185, 129, 0.15);
    color: #10b981;
}

.badge-guides {
    background: rgba(6, 182, 212, 0.15);
    color: #06b6d4;
}

.badge-data {
    background: rgba(239, 68, 68, 0.15);
    color: #ef4444;
}

.card-audience {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(148, 148, 168, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    color: var(--text-secondary);
}

.card-title {
    font-size: 1.25rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 0.75rem;
    line-height: 1.3;
    flex-grow: 1;
}

.card-excerpt {
    font-size: 0.95rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
    line-height: 1.5;
}

.card-footer {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding-top: 1rem;
    border-top: 1px solid var(--border);
    color: var(--text-muted);
    font-size: 0.9rem;
}

.read-time {
    display: flex;
    align-items: center;
    gap: 0.35rem;
}

/* Entity Cards (Browse Pages) */
.entity-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
    gap: 2rem;
}

.entity-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    text-align: center;
    transition: all 0.3s ease;
}

.entity-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.entity-icon {
    font-size: 3rem;
    margin-bottom: 1rem;
}

.entity-card h3 {
    font-size: 1.5rem;
    color: var(--text-primary);
    margin-bottom: 0.5rem;
}

.entity-card p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 0.95rem;
}

.entity-card a {
    display: inline-block;
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border-radius: 0.25rem;
    font-weight: 600;
    transition: all 0.2s ease;
}

.entity-card a:hover {
    background: var(--accent-purple);
}

/* Entity Landing Page */
.entity-landing {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem;
}

.entity-hero-section {
    padding: 3rem 0 2rem 0;
    border-bottom: 1px solid var(--border);
    margin-bottom: 2rem;
}

.entity-hero-content {
    display: flex;
    align-items: center;
    gap: 2rem;
}

.entity-hero-icon {
    font-size: 4rem;
}

.entity-hero-title {
    font-size: 2.5rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.entity-hero-section p {
    color: var(--text-secondary);
    font-size: 1.1rem;
}

/* Active nav item */
.nav-links a.nav-active {
    color: var(--accent-blue);
}

/* Clickable entity card */
.entity-card {
    cursor: pointer;
}

/* Article Page */
.article-page {
    max-width: 900px;
    margin: 0 auto;
    padding: 2rem;
}

.breadcrumb {
    display: flex;
    gap: 0.5rem;
    margin-bottom: 2rem;
    font-size: 0.9rem;
    color: var(--text-secondary);
    flex-wrap: wrap;
}

.breadcrumb a {
    color: var(--accent-blue);
}

.breadcrumb a:hover {
    color: var(--accent-purple);
}

.breadcrumb span {
    margin: 0 0.5rem;
}

.article-header {
    margin-bottom: 2rem;
}

.article-meta-bar {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
    flex-wrap: wrap;
    gap: 1rem;
}

.article-category {
    display: flex;
    gap: 0.75rem;
    align-items: center;
}

.entity-name-display {
    font-size: 1.3rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 1.5rem;
    padding-bottom: 1rem;
    border-bottom: 1px solid var(--border);
}

/* Sibling Navigation */
.sibling-nav {
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
}

.sibling-nav-label {
    font-size: 0.95rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.sibling-pills {
    display: flex;
    gap: 0.75rem;
    flex-wrap: wrap;
}

.sibling-pill {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.6rem 1.2rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 2rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    transition: all 0.2s ease;
    white-space: nowrap;
    cursor: pointer;
}

.sibling-pill a {
    color: inherit;
    text-decoration: none;
}

.sibling-pill:hover {
    border-color: var(--accent-blue);
    color: var(--accent-blue);
}

.sibling-pill.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.sibling-pill.active a {
    color: white;
}

/* Share Bar */
.share-bar {
    display: flex;
    gap: 1rem;
    align-items: center;
    margin-bottom: 2rem;
    padding: 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    flex-wrap: wrap;
}

.share-bar-label {
    font-size: 0.9rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-right: 0.5rem;
}

.share-btn {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.7rem 1.2rem;
    background: var(--bg-secondary);
    border: 1px solid var(--border);
    border-radius: 0.4rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
    white-space: nowrap;
}

.share-btn:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.share-btn.copied {
    background: var(--accent-green);
    border-color: var(--accent-green);
    color: white;
}

.article-content {
    font-size: 1.05rem;
    line-height: 1.8;
    color: var(--text-primary);
}

.article-content h1 {
    font-size: 2.5rem;
    margin-bottom: 1.5rem;
    line-height: 1.2;
    margin-top: 2rem;
}

.article-content h1:first-child {
    margin-top: 0;
}

.article-content h2 {
    font-size: 2rem;
    margin-top: 2rem;
    margin-bottom: 1rem;
    border-bottom: 1px solid var(--border);
    padding-bottom: 0.5rem;
}

.article-content h3 {
    font-size: 1.5rem;
    margin-top: 1.5rem;
    margin-bottom: 0.75rem;
}

.article-content p {
    margin-bottom: 1.25rem;
}

.article-content ul,
.article-content ol {
    margin-left: 2rem;
    margin-bottom: 1.25rem;
}

.article-content li {
    margin-bottom: 0.5rem;
}

.article-content table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content th {
    background: var(--bg-secondary);
    padding: 1rem;
    text-align: left;
    font-weight: 600;
    border: 1px solid var(--border);
}

.article-content td {
    padding: 1rem;
    border: 1px solid var(--border);
}

.article-content blockquote {
    margin-left: 0;
    padding-left: 1.5rem;
    border-left: 3px solid var(--accent-blue);
    color: var(--text-secondary);
    font-style: italic;
    margin-bottom: 1.25rem;
}

.article-content hr {
    border: none;
    height: 1px;
    background: var(--border);
    margin: 2rem 0;
}

.article-content code {
    background: var(--bg-card);
    padding: 0.25rem 0.5rem;
    border-radius: 0.25rem;
    font-family: "Courier New", monospace;
    font-size: 0.9em;
    color: var(--accent-cyan);
}

.article-content pre {
    background: var(--bg-card);
    padding: 1.5rem;
    border-radius: 0.5rem;
    overflow-x: auto;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content pre code {
    background: none;
    padding: 0;
    color: var(--text-primary);
}

/* More in Category */
.more-in-category {
    margin-top: 4rem;
    padding-top: 2rem;
    border-top: 1px solid var(--border);
}

.more-in-category h3 {
    font-size: 1.5rem;
    margin-bottom: 2rem;
}

.more-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
    gap: 2rem;
}

.more-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
}

.more-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
}

.more-card h4 {
    font-size: 1.1rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.more-card p {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.more-card a {
    font-weight: 600;
}

/* Footer */
.site-footer {
    background: var(--bg-secondary);
    border-top: 1px solid var(--border);
    padding: 3rem 2rem;
    margin-top: 4rem;
}

.footer-content {
    max-width: 1400px;
    margin: 0 auto;
}

.footer-disclaimer {
    color: var(--text-secondary);
    font-size: 0.9rem;
    margin-bottom: 1.5rem;
}

.footer-links {
    display: flex;
    gap: 2rem;
    flex-wrap: wrap;
    margin-bottom: 1.5rem;
}

.footer-links a {
    color: var(--text-secondary);
    font-size: 0.9rem;
}

.footer-links a:hover {
    color: var(--text-primary);
}

.back-to-top {
    display: none;
    position: fixed;
    bottom: 2rem;
    right: 2rem;
    width: 3rem;
    height: 3rem;
    background: var(--accent-blue);
    border-radius: 50%;
    color: white;
    align-items: center;
    justify-content: center;
    cursor: pointer;
    z-index: 999;
    transition: all 0.3s ease;
}

.back-to-top:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}

.back-to-top.visible {
    display: flex;
}

/* Pagination */
.pagination {
    display: flex;
    justify-content: center;
    gap: 0.5rem;
    margin: 3rem 0;
}

.pagination a,
.pagination span {
    padding: 0.75rem 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    transition: all 0.2s ease;
}

.pagination a:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.pagination span.current {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Responsive */
@media (max-width: 768px) {
    .header-inner {
        padding: 1rem;
    }

    .nav-links {
        display: none;
        position: absolute;
        top: 4rem;
        left: 0;
        right: 0;
        background: var(--bg-secondary);
        flex-direction: column;
        gap: 0;
        border-bottom: 1px solid var(--border);
        border-radius: 0;
    }

    .nav-links.active {
        display: flex;
    }

    .nav-links li {
        padding: 1rem;
        border-bottom: 1px solid var(--border);
    }

    .nav-toggle {
        display: flex;
    }

    .hero h1 {
        font-size: 2rem;
    }

    .hero .tagline {
        font-size: 1rem;
    }

    .article-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .entity-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .article-page {
        padding: 1rem;
    }

    .article-content h1 {
        font-size: 1.75rem;
    }

    .article-content h2 {
        font-size: 1.5rem;
    }

    .article-meta-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .search-container {
        padding: 0 1rem;
    }

    .filter-buttons {
        overflow-x: auto;
        padding-bottom: 1rem;
    }

    .share-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .sibling-pills {
        overflow-x: auto;
        padding-bottom: 0.5rem;
    }

    .entity-hero-content {
        flex-direction: column;
        text-align: center;
    }

    .entity-hero-title {
        font-size: 2rem;
    }
}

@media (max-width: 480px) {
    .header-inner {
        padding: 0.75rem;
    }

    .site-logo {
        font-size: 1.2rem;
    }

    .hero h1 {
        font-size: 1.5rem;
    }

    .hero-stats {
        grid-template-columns: 1fr;
    }

    .article-grid {
        gap: 1rem;
    }

    .article-content {
        font-size: 1rem;
    }

    .article-content h1 {
        font-size: 1.5rem;
    }

    .article-content h2 {
        font-size: 1.25rem;
    }

    .article-content h3 {
        font-size: 1.1rem;
    }

    .card-title {
        font-size: 1rem;
    }

    .breadcrumb {
        font-size: 0.8rem;
    }

    .sibling-pill {
        padding: 0.5rem 1rem;
        font-size: 0.85rem;
    }

    .share-btn {
        padding: 0.6rem 1rem;
        font-size: 0.85rem;
    }
}

/* PHASE D1: Newsletter CTA */
.newsletter-cta {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2.5rem;
    text-align: center;
    margin: 3rem 0;
    max-width: 600px;
    margin-left: auto;
    margin-right: auto;
}

.newsletter-cta h3 {
    font-size: 1.5rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.newsletter-cta p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 1rem;
}

.newsletter-cta form {
    display: flex;
    gap: 0.5rem;
    flex-direction: column;
}

.newsletter-cta input {
    padding: 0.75rem 1rem;
    background: var(--bg-primary);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-primary);
    font-size: 1rem;
}

.newsletter-cta input::placeholder {
    color: var(--text-muted);
}

.newsletter-cta button {
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border: none;
    border-radius: 0.25rem;
    font-weight: 600;
    cursor: pointer;
    transition: background 0.2s ease;
}

.newsletter-cta button:hover {
    background: var(--accent-purple);
}

/* PHASE F1: Feedback bar */
.feedback-bar {
    display: flex;
    gap: 2rem;
    justify-content: center;
    padding: 2rem 0;
    border-top: 1px solid var(--border);
    margin-top: 3rem;
    flex-wrap: wrap;
}

.feedback-bar a {
    color: var(--text-secondary);
    font-weight: 500;
    transition: color 0.2s ease;
    display: inline-flex;
    align-items: center;
    gap: 0.5rem;
}

.feedback-bar a:hover {
    color: var(--accent-blue);
}

/* PHASE C1: Company view toggles */
.view-toggle-buttons {
    display: flex;
    gap: 1rem;
    justify-content: center;
    margin: 2rem 0;
    flex-wrap: wrap;
}

.view-toggle-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
}

.view-toggle-btn.active {
    background: var(--accent-blue);
    color: white;
    border-color: var(--accent-blue);
}

.view-toggle-btn:hover {
    border-color: var(--accent-blue);
    color: var(--text-primary);
}

.entity-view {
    display: none;
}

.entity-view.active {
    display: block;
}

.sector-group {
    margin-bottom: 3rem;
}

.sector-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

.country-group {
    margin-bottom: 3rem;
}

.country-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

/* Related section for companies */
.related-section {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    margin: 3rem 0;
}

.related-section h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
}

.related-links {
    display: flex;
    flex-direction: column;
    gap: 1rem;
}

.related-links a {
    padding: 1rem;
    background: var(--bg-primary);
    border-radius: 0.25rem;
    color: var(--accent-blue);
    font-weight: 500;
    transition: all 0.2s ease;
    display: flex;
    justify-content: space-between;
    align-items: center;
}

.related-links a:hover {
    background: var(--bg-card-hover);
    color: var(--accent-purple);
}

@media (max-width: 768px) {
    .newsletter-cta {
        padding: 1.5rem;
    }

    .feedback-bar {
        gap: 1rem;
    }

    .view-toggle-buttons {
        gap: 0.5rem;
    }

    .view-toggle-btn {
        padding: 0.6rem 1rem;
        font-size: 0.9rem;
    }
}
</style>
</head>
<body>
    <header class="site-header">
        <div class="header-inner">
            <a href="/" class="site-logo">
                <div class="logo-mark">30</div>
                <div class="logo-text">
                    <div class="logo-text-main">2030</div>
                    <div class="logo-text-sub">Report</div>
                </div>
            </a>
            <nav class="nav-links">
                <li><a href="/">Dashboard</a></li>
                <li><a href="/browse/countries.html">Countries</a></li>
                <li><a href="/browse/companies.html">Companies</a></li>
                <li><a href="/browse/sectors.html">Sectors</a></li>
                <li><a href="/browse/action-plans.html">Action Plans</a></li>
                <li><a href="/browse/guides.html">Guides</a></li>
                <li><a href="/browse/data.html">Data</a></li>
                <li><a href="/about.html">About</a></li>
            </nav>
            <button class="nav-toggle" onclick="toggleNav()">
                <span></span>
                <span></span>
                <span></span>
            </button>
        </div>
    </header>

    <main class="article-page">
        <div class="breadcrumb">
            <a href="/">Home</a><span>/</span><a href="/browse/companies.html">Companies</a><span>/</span><a href="/browse/companies/eli-lilly.html">Eli Lilly</a><span>/</span><span>Employee</span>
        </div>

        <article class="article-header">
            <div class="article-meta-bar">
                <div class="article-category">
                    <span class="card-badge badge-companies">üè¢ Companies</span>
                    <span class="card-audience">üë§ Employee</span>
                </div>
                <div class="read-time">‚è±Ô∏è 12 min read</div>
            </div>

            <div class="entity-name-display">üè¢ Eli Lilly</div>
            
        <div class="share-bar">
            <span class="share-bar-label">Share:</span>
            <button class="share-btn" onclick="copyLink(event)">üìã Copy Link</button>
            <button class="share-btn" onclick="shareOnTwitter()">ùïè Twitter</button>
            <button class="share-btn" onclick="shareOnLinkedIn()">üíº LinkedIn</button>
            <button class="share-btn" onclick="shareOnFacebook()">üìò Facebook</button>
            <button class="share-btn" onclick="shareOnWhatsApp()">üí¨ WhatsApp</button>
            <button class="share-btn" onclick="shareViaEmail()">‚úâÔ∏è Email</button>
        </div>
        
            
        <div class="sibling-nav">
            <div class="sibling-nav-label">All Perspectives:</div>
            <div class="sibling-pills">
                <div class="sibling-pill "><a href="/articles/companies-us-eli-lilly-eli-lilly-ceo.html">CEO</a></div><div class="sibling-pill active"><a href="/articles/companies-us-eli-lilly-eli-lilly-employee.html">Employee</a></div><div class="sibling-pill "><a href="/articles/companies-us-eli-lilly-eli-lilly-investor.html">Analyst</a></div>
            </div>
        </div>
        

            <div class="article-content">
                <h1>ENTITY: ELI LILLY &amp; COMPANY - EMPLOYEE PERSPECTIVE</h1>
<h2>Career Navigation and Organizational Transformation</h2>
<p><strong>MACRO INTELLIGENCE MEMO</strong></p>
<p><strong>FROM:</strong> The 2030 Report<br />
<strong>DATE:</strong> June 2030<br />
<strong>RE:</strong> Eli Lilly - Employee Career Trajectory and Organizational Dynamics in GLP-1 Peak Cycle<br />
<strong>CLASSIFICATION:</strong> Organizational and Career Analysis</p>
<hr />
<h2>EXECUTIVE SUMMARY</h2>
<p>Eli Lilly employees in June 2030 confront a fundamental organizational inflection point: the company is transitioning from GLP-1 growth acceleration (2024-2030) toward patent expiration and pipeline-dependent growth (2032 onward). This transition creates divergent career outcomes by function: exceptional opportunity in drug discovery and research, moderate opportunity in clinical development, constrained opportunity in manufacturing and sales.</p>
<p>The company remains in "peak hiring and expansion" mode in June 2030, but this hiring acceleration is temporary. Following patent expiration (2032-2033), organizational contraction is likely in functions dependent on GLP-1 franchise scale. Career decisions made in 2030 will determine positioning for this transition.</p>
<hr />
<h2>SECTION 1: THE ORGANIZATIONAL PEAK CYCLE AND INFLECTION POINT</h2>
<h3>Current Organizational Status (June 2030)</h3>
<p>Eli Lilly remains in peak expansion mode:<br />
- <strong>Total headcount:</strong> 32,400 employees (up 18% from 2025)<br />
- <strong>R&amp;D investment:</strong> $8.2 billion annually (up 35% from 2025)<br />
- <strong>Capital expenditure:</strong> $4.1 billion (primarily manufacturing expansion)<br />
- <strong>Stock compensation:</strong> Equity grants remain generous; vesting schedules favorable</p>
<p>The company is aggressively hiring, expanding budgets, and investing in infrastructure. For employees in this environment, the conditions are extraordinarily favorable: job security, generous compensation, expanding opportunities, and stock appreciation.</p>
<h3>The Hidden Timeline: 2030-2035 Trajectory</h3>
<p>What is not explicitly communicated to all employees is the company's anticipated trajectory:</p>
<p><strong>Phase 1 (Now through 2032):</strong><br />
- GLP-1 revenue continues growth to peak ($24-26B)<br />
- Hiring accelerates in drug discovery and clinical development<br />
- Manufacturing capacity expanded to handle peak volume<br />
- Pipeline investments continue heavily<br />
- Stock price likely remains elevated</p>
<p><strong>Phase 2 (2032-2034):</strong><br />
- GLP-1 generics begin entering market<br />
- Revenue starts declining (15-20% annually)<br />
- Market begins worrying whether pipeline can fill gap<br />
- Hiring constraints begin<br />
- Stock price begins resetting downward</p>
<p><strong>Phase 3 (2034-2036):</strong><br />
- GLP-1 revenue substantially reduced<br />
- Pipeline drugs' success or failure becomes clear<br />
- Company demonstrates ability to replace GLP-1 or enters slow-growth phase<br />
- Organizational contraction likely if pipeline disappoints<br />
- Stock price volatile pending outcome</p>
<p>For employees, the critical period is 2030-2032: the last genuine expansion period before structural constraints emerge.</p>
<hr />
<h2>SECTION 2: CAREER IMPLICATIONS BY FUNCTION</h2>
<h3>GLP-1 Development and Manufacturing Functions</h3>
<p><strong>Career profile:</strong><br />
- Present work: Exceptionally exciting‚Äîdriving global blockbuster drug<br />
- Compensation: Among highest at company<br />
- Growth opportunity: Limited after 2032<br />
- Risk profile: Moderate-high</p>
<p><strong>Timeline for function:</strong><br />
- 2024-2032: Peak growth and expansion; team hiring, headcount expansion<br />
- 2032-2033: Generic entry; declining volumes; team stabilization<br />
- 2033-2035: Further volume decline; likely team reductions</p>
<p><strong>Career decision framework:</strong></p>
<p>For employees in GLP-1 development/manufacturing:<br />
- <strong>If early career (&lt;5 years):</strong> Stay through 2032; build expertise in global blockbuster<br />
- <strong>If mid-career (5-10 years):</strong> Consider transitioning to growth functions now (drug discovery, clinical); secure positioning before team constraints emerge<br />
- <strong>If late career (10+ years):</strong> Current role secure through 2032; consider next chapter timing</p>
<p><strong>Key insight:</strong> If you're in GLP-1 functions and see yourself at Eli Lilly in 2035, begin transitioning now. Your current function will contract; the company's future is not in GLP-1 manufacturing.</p>
<h3>Clinical Research and Trial Functions</h3>
<p><strong>Career profile:</strong><br />
- Present work: Critical to pipeline advancement; heavily invested<br />
- Compensation: Growing faster than company average (competitive for talent)<br />
- Growth opportunity: Moderate; dependent on pipeline success<br />
- Risk profile: Moderate</p>
<p><strong>Skill requirements evolution:</strong><br />
- Traditional clinical trial skills (patient recruitment, data management) remain important<br />
- New methodology skills critical: adaptive trial designs, real-world data integration, AI-enabled trial optimization<br />
- Career trajectory: Those adapting to new methodologies advance; those remaining committed to traditional approaches face skill obsolescence</p>
<p><strong>Career decision framework:</strong><br />
- <strong>If interested in traditional trial methodology:</strong> Skills remain valuable through 2035, but advancement opportunity limited<br />
- <strong>If interested in AI-enabled trial optimization:</strong> Demand accelerating; career opportunities expanding; compensation growing; positioning excellent</p>
<p><strong>Key insight:</strong> Clinical research skills are currently in demand. But the skill set that matters is evolving. Those who invest in learning adaptive designs, real-world data, and AI-enabled approaches will have superior career prospects.</p>
<h3>Drug Discovery and Research Functions</h3>
<p><strong>Career profile:</strong><br />
- Present work: Most critical for company's future<br />
- Compensation: Aggressive; hiring at premium rates (competing with tech companies for AI talent)<br />
- Growth opportunity: Exceptional<br />
- Risk profile: Low</p>
<p><strong>Investment in discovery functions:</strong><br />
- Company hiring aggressively in computational biology, AI/ML scientists, structural biologists<br />
- R&amp;D budget expanding specifically in discovery<br />
- Compensation increases 8-12% annually (to attract and retain talent)<br />
- International expansion of research centers</p>
<p><strong>Career trajectory:</strong><br />
- Exceptional opportunity for advancement<br />
- Career progression accelerated vs. other functions<br />
- Leadership opportunities abundant<br />
- Long-term job security excellent</p>
<p><strong>Career decision framework:</strong><br />
- <strong>If you work in discovery:</strong> You are in the most valuable function for company's future. Advancement opportunity is exceptional. This is where the company's future is being determined.<br />
- <strong>If you're considering moving into discovery:</strong> Now is the optimal time. The company is aggressively recruiting and investing.</p>
<p><strong>Key insight:</strong> Drug discovery is where the company's future is being determined. Those positioned in discovery will have exceptional career prospects whether the company succeeds (promotion and advancement) or struggles (portability of research credentials).</p>
<h3>Manufacturing and Supply Chain Functions</h3>
<p><strong>Career profile:</strong><br />
- Present work: Essential to GLP-1 scaling<br />
- Compensation: Market-competitive but not premium<br />
- Growth opportunity: Moderate through 2032; declining after<br />
- Risk profile: Moderate-high</p>
<p><strong>Timeline:</strong><br />
- 2024-2032: Growth phase; manufacturing excellence critical; investment abundant<br />
- 2032 onward: Manufacturing optimization ongoing, but growth headroom diminished</p>
<p><strong>Career decision framework:</strong><br />
- <strong>If early career:</strong> Build expertise in modern manufacturing; this is valuable across companies<br />
- <strong>If mid-late career:</strong> Consider transitioning to functions less exposed to GLP-1 volume decline<br />
- <strong>If you want to remain in manufacturing:</strong> Build expertise in new drug manufacturing (pipeline candidates require different manufacturing approaches)</p>
<p><strong>Key insight:</strong> Manufacturing remains essential, but the function will experience slower growth post-2032. Those who develop expertise in diverse manufacturing approaches (vs. pure GLP-1 specialization) have more career optionality.</p>
<h3>Sales and Commercial Functions</h3>
<p><strong>Career profile:</strong><br />
- Present work: Exciting; driving blockbuster sales<br />
- Compensation: Bonus-driven; significant upside opportunity<br />
- Growth opportunity: Strong through 2031; constrained after<br />
- Risk profile: Moderate-high</p>
<p><strong>Career dynamics:</strong><br />
- 2024-2031: GLP-1 sales growth drives compensation; territory expansion creates opportunity<br />
- 2031-2032: Sales growth deceleration; bonus structures stress<br />
- 2032-2034: GLP-1 competition intensifies; Novo Nordisk and others capture share; compensation pressure</p>
<p><strong>Career decision framework:</strong><br />
- <strong>If you love current environment:</strong> Enjoy it for next 18-24 months; position yourself for transition after<br />
- <strong>If you're building book of business:</strong> Excellent opportunity to build customer relationships that will persist beyond GLP-1 cycle<br />
- <strong>If you want long-term career growth:</strong> Consider moving into functions less GLP-1-dependent</p>
<p><strong>Key insight:</strong> Sales is exciting now, but the function will face headwinds post-2032. Those who build relationships with customers (beyond GLP-1) and develop consultative selling skills have more career options.</p>
<h3>Corporate and Administrative Functions</h3>
<p><strong>Career profile:</strong><br />
- Present work: Steady; company growing around you<br />
- Compensation: Market-competitive; not premium<br />
- Growth opportunity: Limited; functions grow slower than product development<br />
- Risk profile: Low-moderate</p>
<p><strong>Timeline:</strong><br />
- 2024-2032: Steady expansion; roles expanding; limited downsizing<br />
- 2032-2034: If company needs to right-size, administrative functions often affected<br />
- 2034+: Dependent on company's overall growth</p>
<p><strong>Career decision framework:</strong><br />
- <strong>If you love the work:</strong> Stay; job security reasonable through 2032<br />
- <strong>If you want growth opportunity:</strong> Consider moving to product-related functions<br />
- <strong>If concerned about job security in tight times:</strong> Administrative functions often first targets for downsizing</p>
<p><strong>Key insight:</strong> Corporate functions are stable but not growth-oriented. If you want visible growth opportunity and job security, move to drug discovery or clinical development.</p>
<hr />
<h2>SECTION 3: THE ORGANIZATION'S CULTURAL TRANSITION</h2>
<h3>Culture in Peak Growth Mode (2024-2030)</h3>
<p>Eli Lilly culture during GLP-1 expansion:<br />
- <strong>Optimism:</strong> Company is winning; market is validating strategy; confidence is high<br />
- <strong>Speed:</strong> Rapid decision-making; aggressive timelines; "move fast" mentality<br />
- <strong>Abundance:</strong> Budgets generous; hiring aggressive; investment abundant<br />
- <strong>Hierarchy:</strong> Traditional pharma hierarchy but softened by growth dynamics</p>
<h3>Anticipated Culture in Transition (2032-2035)</h3>
<p>When company transitions from growth to efficiency:<br />
- <strong>Constraint:</strong> Budgets tightened; hiring constrained; efficiency focus<br />
- <strong>Discipline:</strong> Longer decision timelines; cost scrutiny; ROI focus<br />
- <strong>Scarcity:</strong> Budgets compete; hiring selective; investment scrutinized<br />
- <strong>Reorganization:</strong> Restructuring to optimize for post-GLP-1 reality</p>
<p>The culture will shift from "how can we expand faster" to "how can we be more efficient with existing resources."</p>
<hr />
<h2>SECTION 4: STOCK COMPENSATION AND EQUITY UPSIDE</h2>
<h3>Current Stock Appreciation and Equity Grants</h3>
<p>Employees granted equity in 2024-2026 have experienced substantial stock appreciation:<br />
- Stock price 2024: $425<br />
- Stock price June 2030: $720 (+69%)<br />
- For employees with early equity grants: Cumulative wealth creation substantial</p>
<p><strong>Equity value realization:</strong> Those planning to exercise options should consider:<br />
- Stock upside likely constrained (current valuation reflects optimistic consensus)<br />
- Patent expiration (2032-2033) likely creates downside risk<br />
- Equity granted in 2030 will appreciate more modestly than 2024-2026 grants</p>
<h3>Vesting and Exercise Strategy</h3>
<p>For employees with unvested equity or near-term vesting:<br />
- <strong>Accelerated vesting:</strong> Some companies offer accelerated vesting during transitions; negotiate if possible<br />
- <strong>Exercise timing:</strong> Holding equity during 2032-2034 transition period carries downside risk<br />
- <strong>Diversification:</strong> Consider taking profits on appreciated equity; diversify wealth</p>
<p><strong>Key insight:</strong> Your unvested equity represents significant wealth. The company's stock price could appreciate 20-30% short-term (next 18 months) but face compression 30-40% longer-term (2033-2035). Consider your personal wealth allocation and risk profile in exercising equity.</p>
<hr />
<h2>SECTION 5: THE HONEST ASSESSMENT AND CAREER DECISION FRAMEWORK</h2>
<h3>Where the Company Is in Its Lifecycle</h3>
<p>Eli Lilly is at the <strong>peak of its current cycle</strong>. The company is at maximum scale on its blockbuster franchise, maximum profitability, maximum stock price valuation.</p>
<p>This is not a negative assessment‚Äîthe company is genuinely excellent with exceptional execution. But "peak" means inflection is coming.</p>
<p><strong>For employees:</strong> Peak cycle is the best environment. Budgets are generous. Growth is evident. Stock appreciation is substantial. Compensation is expanding.</p>
<p>The window for enjoying peak cycle dynamics is 18-24 months (through 2032). After that, the organizational environment changes.</p>
<h3>Critical Career Decision: Stay or Leave?</h3>
<p><strong>Stay if:</strong><br />
- You work in drug discovery, research, or clinical development (these functions have long-term growth)<br />
- You're early in your career and want to learn pharma (Eli Lilly is excellent for this)<br />
- You believe in the company's ability to build a strong pipeline<br />
- You can tolerate organizational transition risk in exchange for optionality</p>
<p><strong>Leave if:</strong><br />
- You work in functions likely to be downsized post-2032 (manufacturing, sales, corporate)<br />
- You want to work for a company in pure growth mode (not at inflection point)<br />
- You don't believe the pipeline will successfully replace GLP-1 revenue<br />
- You want maximum career growth optionality (consider opportunities elsewhere)</p>
<p><strong>Stay neutral (undecided):</strong><br />
- Make the decision consciously in next 18-24 months<br />
- Don't drift into 2032 without making intentional choice<br />
- The company will still be here; the opportunity cost is not reversible</p>
<hr />
<h2>SECTION 6: MAXIMIZING VALUE DURING PEAK CYCLE</h2>
<h3>The Next 18-24 Months Are Critical</h3>
<p>If you decide to stay at Eli Lilly, maximize value during the next 18-24 months:</p>
<ol>
<li><strong>Build expertise:</strong> Invest in developing skills valuable beyond Eli Lilly (drug discovery, clinical methodology, manufacturing excellence)</li>
<li><strong>Build network:</strong> Develop relationships across company and industry; these relationships are valuable for future opportunities</li>
<li><strong>Capture compensation upside:</strong> Bonus structures likely most generous during this period; perform at highest level</li>
<li><strong>Secure equity upside:</strong> Maximize equity grants before transition reduces grant values</li>
</ol>
<h3>If You Decide to Leave</h3>
<p>If you decide Eli Lilly's future doesn't align with your career goals:</p>
<ol>
<li><strong>Leave on your terms:</strong> Don't wait for layoffs; leave proactively while company is still hiring (easier transitions)</li>
<li><strong>Develop external opportunities:</strong> Network with competitors, other pharma companies, startups</li>
<li><strong>Build case studies:</strong> Document projects and outcomes that demonstrate your capability</li>
</ol>
<hr />
<h2>CONCLUSION</h2>
<p>Eli Lilly employees in June 2030 have remarkable opportunity to work for a world-class organization at peak performance. The company is profitable, growing, investing heavily, and generating stock appreciation.</p>
<p>But this is a temporary window. By 2032-2033, organizational dynamics will shift as patent expiration creates headwinds. The functions and individuals positioned to succeed in that environment will prosper. Those not positioned will face constraints.</p>
<p>The honest assessment: <strong>The next 12 months will be the best it gets for a while. The company is throwing money at every opportunity. Budgets are generous. Hiring is aggressive. After 2032, the environment becomes more selective and competitive.</strong></p>
<p>Make your career decisions consciously. Consider your positioning for the 2032-2035 transition. Invest in skills valuable beyond the current moment. Build relationships that will serve you whatever your next chapter is.</p>
<p>The company will be fine. Whether <em>you're</em> fine depends on the decisions you make in the next 18-24 months.</p>
<hr />
<p><em>The 2030 Report | Organizational and Career Analysis</em></p>
<p><strong>Word Count: 2,634</strong></p>
<hr />
<h2>WHAT YOU SHOULD DO NOW</h2>
<p>The window for proactive career management is open now but narrowing. Here's your action plan:</p>
<p><strong>Audit your role honestly:</strong> Break your job into its component tasks. Which ones could an AI system handle today? Which ones could it handle in 2-3 years? The tasks that remain ‚Äî complex judgment, relationship management, creative problem-solving, ethical decision-making ‚Äî are where you need to concentrate your value.</p>
<p><strong>Become AI-augmented, not AI-replaced:</strong> Start using AI tools in your current role today. Learn prompt engineering, AI-assisted analysis, and AI-augmented workflows. The goal is to become the person who accomplishes with AI what used to require a team of five.</p>
<p><strong>Invest in reskilling:</strong> Identify the skills that your industry will need in 2028-2030 and start building them now. Online courses, certifications, side projects ‚Äî the investment is small compared to the cost of being displaced.</p>
<p><strong>Negotiate from strength:</strong> If your company is investing in AI transformation, volunteer for AI pilot projects. If they're not investing, that's a signal about your long-term job security there.</p>
<p><strong>Build your network:</strong> In a disrupted labor market, who you know matters more than ever. Build relationships across your industry, especially with people at companies that are leading AI transformation.</p>
<p><strong>Have a financial buffer:</strong> Save aggressively. If your role is at risk, having 6-12 months of expenses saved gives you the freedom to retrain or transition on your own terms rather than under duress.</p>
<p><em>Read more: Browse all <a href="/browse/sectors.html">Employee-focused memos</a> across 20 sectors to understand how your specific industry is being transformed.</em></p>
            </div>
        </article>

        <div style="margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border); text-align: center;"><a href="/browse/companies/eli-lilly.html" style="display: inline-block; padding: 1rem 2rem; background: var(--bg-card); border: 1px solid var(--border); border-radius: 0.5rem; color: var(--text-primary); font-weight: 600; transition: all 0.2s ease;">‚Üê All Eli Lilly Articles</a></div>
        
        <div class="more-in-category">
            <h3>More in Companies</h3>
            <div class="more-grid">
                
            <div class="more-card">
                <h4>ENTITY: APPLE CORPORATION</h4>
                <p>FROM: The 2030 Report, Technology & Market Analysis Division</p>
                <a href="/articles/companies-us-apple-apple-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>From: The 2030 Report Global Intelligence Division</p>
                <a href="/articles/companies-us-apple-apple-investor.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>---</p>
                <a href="/articles/companies-us-apple-apple-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: THE HOME DEPOT INC.</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>HOME DEPOT: WORKFORCE RESTRUCTURING IN HOUSING DOWNTURN</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: Home Depot, Inc. | Housing Market Downturn and Structural Retail Transformation</h4>
                <p>FROM: The 2030 Report | Retail and Consumer Spending Analysis</p>
                <a href="/articles/companies-us-home-depot-home-depot-investor.html">Read more ‚Üí</a>
            </div>
            
            </div>
        </div>
        
    </main>

    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-disclaimer">
                <strong>Disclaimer:</strong> This report provides forecasts and analysis of AI disruption trends. Predictions are based on current data and expert analysis but are subject to change. Use this information for informational purposes only.
            </div>
            <div class="footer-links">
                <a href="/">Home</a>
                <a href="/browse/countries.html">Countries</a>
                <a href="/browse/companies.html">Companies</a>
                <a href="/browse/sectors.html">Sectors</a>
                <a href="/browse/action-plans.html">Action Plans</a>
                <a href="/browse/guides.html">Guides</a>
                <a href="/browse/data.html">Data</a>
                <a href="/about.html">About</a>
            </div>
            <div style="color: var(--text-muted); font-size: 0.85rem; margin-top: 1rem;">
                &copy; 2030 Intelligence Report. All rights reserved.
            </div>
        </div>
    </footer>

    <button class="back-to-top" onclick="scrollToTop()" title="Back to top">‚Üë</button>

    <script>
        function toggleNav() {
            const navLinks = document.querySelector('.nav-links');
            navLinks.classList.toggle('active');
        }
        // Highlight active nav item
        document.querySelectorAll('.nav-links a').forEach(link => {
            const href = link.getAttribute('href');
            const path = window.location.pathname;
            if (href === '/' && path === '/') link.classList.add('nav-active');
            else if (href !== '/' && path.startsWith(href.replace('.html', ''))) link.classList.add('nav-active');
        });

        function scrollToTop() {
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }

        function copyLink(e) {
            const url = window.location.href;
            const btn = e.currentTarget;
            navigator.clipboard.writeText(url).then(() => {
                const originalText = btn.innerText;
                btn.innerText = '‚úì Copied!';
                btn.classList.add('copied');
                setTimeout(() => {
                    btn.innerText = originalText;
                    btn.classList.remove('copied');
                }, 2000);
            });
        }

        const pageTitle = document.title.split(' - ')[0];

        function shareOnTwitter() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://twitter.com/intent/tweet?text=${text}`, '_blank');
        }

        function shareOnLinkedIn() {
            const url = window.location.href;
            window.open(`https://www.linkedin.com/sharing/share-offsite/?url=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnFacebook() {
            const url = window.location.href;
            window.open(`https://www.facebook.com/sharer/sharer.php?u=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnWhatsApp() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://wa.me/?text=${text}`, '_blank');
        }

        function shareViaEmail() {
            const url = window.location.href;
            window.location.href = `mailto:?subject=${encodeURIComponent(pageTitle)}&body=${encodeURIComponent('Check this out: ' + url)}`;
        }

        window.addEventListener('scroll', () => {
            const backToTop = document.querySelector('.back-to-top');
            if (window.scrollY > 300) {
                backToTop.classList.add('visible');
            } else {
                backToTop.classList.remove('visible');
            }
        });

        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({ behavior: 'smooth' });
                }
            });
        });
    </script>
</body>
</html>
